Breast Cancer
Conditions
Keywords
neo adjuvant, breast cancer
Brief summary
The scope of this registry study is to measure chemosensitivity as defined by pCR (primary endpoint), or endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1), a primary endpoint for neo-adjuvant endocrine therapy and a secondary endpoint for neoadjuvant chemotherapy), metastasis-free survival and relapse-free survival(secondary endpoints) in molecular subgroups, determined by the established MammaPrint, BluePrint, Targetprint and Theraprint profiles in addition to possible novel expression profiles.
Detailed description
This will be a prospective observational, case-only study linking MammaPrint, BluePrint, TargetPrint, TheraPrint and possible additional profiles of interest to treatment response and Distant Metastases Free Survival (DMFS) and Relapse Free Survival (RFS). Only patients who receive neo-adjuvant therapy can participate. For this project, approximately 50-70 institutions in the US will be invited to contribute clinical patient data from enrolled patients after a MammaPrint, TargetPrint, BluePrint and TheraPrint test has been successfully performed and the patient has started neo-adjuvant therapy. Treatment is at the discretion of the physician, adhering to NCCN approved regimens or a recognized alternative. The clinical data is to be entered online at 4 time points; amounting to four Case Report Forms (CRFs). Data will be collected on an ongoing basis, the first CRF must be completed within 6 weeks after the MammaPrint, BluePrint, TargetPrint, and TheraPrint result was provided. The second CRF should be completed 4 weeks after definitive surgery. CRF 3 and CRF4 will be completed 2-3 and 5 years after surgery. It is expected that we will enroll around 1000 patients in 4 years. OBJECTIVES * Measure chemosensitivity (as defined by pCR) or endocrine sensitivity (as defined by decrease in longest tumor diameter or RCB1)in the molecular subgroups as determined by combining MammaPrint and BluePrint results. * Correlate chemosensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results. * Compare local IHC and FISH results (if available) with TargetPrint results. Compare the three BluePrint molecular subgroups with IHC-based subtype classification. * Document impact of MammaPrint, TargetPrint and BluePrint result on treatment decision. * Assess the 2-3 and 5 years DMFS and RFS for the different molecular subgroups. * Measure chemosensitivity or endocrine sensitivity correlation with novel expression profiles.
Interventions
OTHERMammaPrint 70-gene expression profile
OTHERBluePrint 80 gene expression profile
Sponsors
Agendia
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Women with histologically proven breast cancer, who have started or are scheduled to start neo-adjuvant chemotherapy therapy or neo-adjuvant hormone therapy, after successful MammaPrint assay * Age 18-90 * Written informed consent
Exclusion criteria
* Patients who have had excisional biopsy or axillary dissection Patients with confirmed distant metastatic disease * Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria * Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer * Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chemosensitivity as defined by pCR | Up to 6 months | For neo-adjuvant chemotherapy patients the primary endpoint is pathological complete response (pCR) which is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ. The response rate and corresponding confidence intervals will be presented as a proportion of all patients enrolled. Comparison of response rates between different molecular subgroups will be conducted using Pearson Chi-square test. |
| Endocrine sensitivity as defined by partial response (decrease in longest tumor diameter or residual cancer burden category 1 (RCB1) | Up to 6 months | The primary endpoint for patients with neo-adjuvant hormonal therapy is partial response which is defined as decrease in longest tumor diameter. The response rate and corresponding confidence intervals will be presented as a proportion of all patients enrolled. Comparison of response rates between different molecular subgroups will be conducted using Pearson Chi-square test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare local IHC and FISH results (if available) with TargetPrint results. | Baseline; before start of neo-adjuvant therapy. | Correlation of TargetPrint ER, PR, and HER2 microarray readout with IHC/FISH assessment will be determined using Pearson correlation and linear fit models. Agreement measurements between binary microarray and IHC classifications will be based on 2-way contingency table analysis and include overall concordance, positive agreement defined as the number of samples classified positive by both IHC and TargetPrint divided by the number of positive samples using IHC, negative agreement and Cohen's Kappa coefficient score. |
| Correlate chemosensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results. | Up to 6 months. | Correlation of chemosensitivity and endocrine sensitivity (as defined by pCR) to TheraPrint Therapy Gene Assay results will be determined using Pearson correlation and linear fit models. |
| Document impact of MammaPrint, TargetPrint and BluePrint result on treatment decision. | Baseline; before start neo-adjuvant therapy. | Review the impact of MammaPrint, TargetPrint, and BluePrint on physician treatment decisions. |
| Compare the three BluePrint molecular subgroups with IHC-based subtype classification. | Baseline; before start of neo-adjuvant therapy. | Correlation of BluePrint molecular subgroup microarray readout with IHC-based subtype classification. |
| Assess metastasis-free survival and relapse-free survival in molecular subgroups, determined by the established MammaPrint, BluePrint, profiles. | At -2-3 years and 5 years after definitive surgery. | Kaplan-Meier curves for DMFS will be calculated for the following eight subgroups 1. Luminal subtype 2. ERBB2 subtype 3. Basal subtype 4. Luminal subtype and high risk MammaPrint 5. Luminal subtype and low risk MammaPrint 6. ERBB2 subtype and high risk MammaPrint 7. ERBB2 subtype and low risk MammaPrint |
Countries
United States
Outcome results
None listed